Dr. Lal Pathlabs Limited · NSE:LALPATHLAB
Dr. Lal Pathlabs — Q2 FY21 Earnings Presentation
30 slides from Dr. Lal Pathlabs's earnings presentation, Nov 6, 2020
Slide 1: Cover letter to stock exchanges
November 6, 2020 National Stock Exchange of India Bombay Stock Exchange Limited Limited Exchange Plaza, Corporate Relationship Department Plot No. C/1, G Block, Phiroze Jeejeebhoy Towers Sandra Kurla Complex Sandra (E) Dalal Street Mumbai - 400 051. Mumbai- 400001 Subject: Investors Presentation on
Slide 2: Q2 FY21 Results Presentation
Dr. Lal PathLabs Limited (DLPL) Q2 FY21 Results Presentation November 6, 2020
Slide 3: Disclaimer
Disclaimer By attending the meeting / telephonic call where this presentation is made, or by reading the presentation materials, you agree to be bound by the following limitations: The information in this presentation has been prepared by Dr. Lal PathLabs Limited (the “Company”) for use in presentat
Slide 4: Q2 FY21 Snapshot
Q2 FY21 Snapshot 18.2% 18.7% *7.5% INR 431.9 Cr INR 134.7 Cr INR 87.1 Cr Revenues Normalised EBITDA* PAT 1.1% 1.1% ~ 5.4 mn ~ 13.2 mn Patients Samples * PAT in Q2 last year has high base due to Income tax rates reduction benefit pertaining to Q1 as well 3
Slide 5: Table of Contents
Table of Contents Dr. Lal PathLabs – At a Glance 5 Overview of Dr. Lal PathLabs 6 Key Performance Highlights 8 Financials 9 Financial Highlights 10 Operating Highlights 12 Management Commentary 13 Vibrant Outlook 14 Corporate Overview 16 Shareholding 27 Contact Us 29 DISCLAIMER: This presentation ma
Slide 6: Dr. Lal PathLabs – At a Glance
Dr. Lal PathLabs – At a Glance India’s Leading & Trusted 12% 15% 120% Diagnostics Company Largest* 3 Year Revenue 3-Year PAT Equity Dividend CAGR CAGR for FY 19-20 diagnostics 70+ years of experience chain in the in the field of diagnostics country with ~67% Rs 894.1 Cr. PAN India ROCE Cash & Invest
Slide 7: Overview of Dr. Lal PathLabs
Overview of Dr. Lal PathLabs Established brand Pan-India integrated Varied Offerings Unique and successful coverage operating model 216 clinical labs (including National Reference Lab at Catalogue of 455 test panels, Scalable model integrated Established consumer Delhi and Regional Reference 2,537 p
Slide 8: COVID & Non-COVID Revenue
COVID & Non-COVID Revenue 568 • Non-COVID business back to 98% of last year levels in Q2 FY21 • Contribution from COVID business in Q2 358 FY21 is ~17%. 210 • 3.08 lac COVID RTPCR tests conducted in 130 Q2 FY21 and 5.05 lac in FH FY21 56 74 • RT-PCR test being conducted in 9 labs. • Commenced on-dem
Slide 9: Key Performance Highlights
Key Performance Highlights During Q2 FY21: • Revenues increased by 18.2% Y-o-Y at Rs. 431.9 crore • Normalised EBITDA (after eliminating the impact of stock based compensation & CSR) at Rs. 134.7 crore • Profit After Tax at Rs. 87.1 crore, representing a growth of 7.5% over the corresponding quarter
Slide 10: Financials
Financials Particulars (Rs. Cr.) Q2 FY21 Q2 FY20 Gr % FH FY21 FH FY20 Gr % Total Revenue 431.9 365.6 18.2% 697.9 700.8 -0.4% Total Expenditure 304.7 256.7 522.4 496.8 EBITDA 127.3 108.9 16.9% 175.5 204.0 -14.0% Adj for Stock based comp. & CSR cost 7.4 4.6 13.0 8.5 Normalised EBITDA 134.7 113.5 18.7%
Slide 11: Financial Highlights
Financial Highlights All figures in Rs. Crore +18.2% • Revenue increased in Q2 FY21 by 18.2% to Rs. 431.9 431.9 crore. This is on account of : – Volumes which increased by 1.1% and – Revenue from COVID testing Revenue 365.6 • Realisation per patient in Q2 FY21 at Rs. 803, higher as compared to Rs. 6
Slide 12: Financial Highlights
Financial Highlights All figures in Rs. Crore +14.0% • PBT for Q2 FY21 at Rs. 116.6 crore vs. Rs. 102.3 crore in 116.6 the corresponding quarter of last year, representing a growth of 14.0% PBT • Q2 FY21 PBT margin at 27.0%, as against 28.0% in the 102.3 same period of last year Q2 FY20 Q2 FY21 +7.5
Slide 13: Operating Highlights
Operating Highlights No. of Clinical Laboratories No. of PSCs No. of PUPs +23 +942 +1,371 193 200 216 3,095 6,426 6,995 2,569 5,624 2,153 FY18 FY19 FY20 FY18 FY19 FY20 FY18 FY19 FY20 No. of Patients (Mn) No. of Samples (Mn) +28% +37% 17.6 19.4 47.7 15.2 41.8 34.7 8.9 21.1 FY18 FY19 FY20 FY21 FY18 FY
Slide 14: Management Commentary
Management Commentary Commenting on the results announcement, (Hony) Brig. Dr. Arvind Lal, Executive Chairman “The CoVID-19 pandemic has been fairly prolonged not only affecting the daily lives of people but also impacting the businesses and economies across the globe. Q2 saw the lockdown being lift
Slide 15: Vibrant Outlook
Vibrant Outlook Strongly develop Rest of India geographies, through Regional Reference Labs and cluster city approach for attractive markets Target to grow Evaluate best fit inorganic Deeper Penetration within the ahead opportunities in South & West North, East & Central Indian of the markets indust
Slide 16: Leveraging digital to make life easier for patient
Leveraging digital to make life easier for patient Logistics Lab Operations Business Digital Lab e-Commerce Mobile app Automation Automation Continuity Plan • Self Registration • Online test / health • Test booking, view • Field Executive • Totally integrated • ‘Multi Site’ model Kiosk for patients
Slide 17: Corporate Overview
Corporate Overview 16
Slide 18: Vision, Mission & Values
Vision, Mission & Values VISION Customer First Be the most trusted healthcare partner, enabling healthier lives Ethics & Integrity VALUES Quality To be the undisputed market leader by providing accessible, affordable, timely and quality healthcare, Accountability diagnostics, applying insights and c
Slide 19: DLPL Strategy for future growth
DLPL Strategy for future growth 1 2 Strengthen Expansion in Existing Offering Operations Expand 4 3 management of Geographic hospital based expansion and clinical laboratories 18
Slide 20: DLPL Strategy for future growth
DLPL Strategy for future growth Expand management of hospital Strengthen Existing Operations Expansion in Offering Geographic expansion based and clinical laboratories Boosting quality & reliability Improve breadth of Tap incremental contracts for Focus city & cluster approach standards diagnostic t
Slide 21: Consistent investments in R&D
Consistent investments in R&D DSIR recognized In House R&D unit R&D Collaboration with marquee Successful commercialization of with an experienced team of institutions tests research scientists and doctors Jawaharlal Nehru University for development of diagnostics kit for detection of mycobacterium
Slide 22: Genevolve: The Genomics initiative
Genevolve: The Genomics initiative GENEVOLVE brings the dawn of a new era of Genomic testing! Genevolve: Genomics division focuses on Genetic testing Offers wide range of key tests related to Oncogenomics, Neurogenomics, Rare disease & Pre-natal/ Post-natal New Tests New Tie-ups ONCOPATH • Sperm DNA
Slide 23: In-house adoption of Digital Histopathology
In-house adoption of Digital Histopathology Reporting of Digital Opportunities created by Breast cancer Panels Digital Histopathology using AI based algorithms Digital Histopathology • Enhanced access to second for remote routine opinion, synchronous review reporting of slides • Enhanced quality
Slide 24: Highest Quality Standards in the Industry
Highest Quality Standards in the Industry 100+ Quality Digitally enabled Real time quality Risk based improvement solutions control quality assurance meetings on a daily implemented for monitoring framework basis with the quality audits network partners and trainings Best in the Industry CAP Profici
Slide 25: Best in class Logistics and Supply Chain management
Best in class Logistics and Supply Chain management Real Real time time service sample monitoring tracking Control tower Real time Field Automated Cash Productivity Executive collection and route tracking process planning with clients visibility 24
Slide 26: Enhanced Customer Experience in Home Collection
Enhanced Customer Experience in Home Collection Auto Routing engine to dynamically allocate the booking to nearest available phlebotomist Real time slot confirmation Real time phlebo visibility to to patient the patient Variable model which grows ECG at home service with business volume launched in
Slide 27: Experienced Management team
Experienced Management team (Hony.) Brig. Dr. Arvind Lal Dr. Om Manchanda Dr. Vandana Lal Bharath Uppiliappan Ved Prakash Goel Executive Chairman Managing Director Whole-time Director Chief Executive Officer Chief Financial Officer Shankha Banerjee Munender Soperna Rajat Kalra Manoj Garg Company Sec
Slide 28: Shareholding as of 30th September, 2020
Shareholding as of 30th September, 2020 22.4% FIIs 14.1% 55.2% Others Promoter and Promoter Group 8.3% Mutual Funds* *Mutual Funds includes Alternate Investment Funds as well 27
Slide 29: Key Awards & Recognition
Key Awards & Recognition Dr. Om Manchanda honoured ICICI Lombard & CNBC EY Entrepreneur of The Data Quest Technology VC Circle Healthcare and awarded as ‘Healthcare TV18 India Risk Year 2019 – Life Award 2015 – Excellence Summit 2013 – Best Personality of the Year, 2020’ Management Awards 2020 Scien
Slide 30: Contact Us
Contact Us About Dr. Lal PathLabs Limited (DLPL) Dr. Lal PathLabs Limited is one of India’s leading consumer healthcare brand in diagnostic services. It has an integrated nationwide network, where patients and healthcare providers are offered a broad range of diagnostic and related healthcare tests